NCT01109069 2020-05-27Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic LeukemiaPharmacyclics LLC.Phase 2 Completed199 enrolled 14 charts
NCT02129062 2017-01-16Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)Phase 2 Terminated3 enrolled 4 charts
NCT02109224 2015-08-20Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionNational Cancer Institute (NCI)Phase 1 Terminated72 enrolled